stage

AIN
IonescuTx

IonescuTx

location_on Oeste ,  Estados Unidos

Por favor toma nota:
Invirtiendo en empresas jóvenes lleva riesgos como falta de liquidez, falta de dividendos, pérdida de inversión y dilución. Debería hacer parte de un portafolio diversificado. La plataforma está dirigida únicamente a inversores sofisticados que entienden estos riesgos y pueden hacer sus propios decisiones cuando están invirtiendo. Esta información no ha sido aprobada como una promoción financiera y Ud. tiene que hacer su propia diligencia debida.

Resumen corto

The goal of IonescuTx is to discover disease-modifying small-molecule therapeutics for late-onset Alzheimer's Disease (LOAD). We are focused on correcting ApoE4 function to stop lipid dysregulation in the brain that leads to neurodegeneration.

Puntos claves

  • ApoE4 is the strongest genetic risk factor for Alzheimer's disease
  • Current approaches focus on plaques and aggregates, which lack efficacy
  • Substantial evidence suggests ApoE4 causes Alzheimer's disease progression
  • Our approach is to correct ApoE4 function to stop Alzheimer's progression
  • We will discover and develop small molecule modulators of ApoE4

Resumen

Objetivo €8,500,000
Mínimo €9,000
Inversión recaudada €0
Rondas anteriores €0
Fase Pre-lanzamiento/R&D
Función del inversor Any

Haga una pregunta
¿Tiene alguna pregunta?

Propuestas Similares

The in Between

The in Between

location_onGauteng, Sudáfrica

Serving South Africans unable to afford private services but are able to pay for semi-private alternatives, such as affordable schools. A joint pharmacy venture with the State—providing not free but reliable, accessible, and fairly priced medicines.

  • Quality education for families between public & private options
  • Smaller classes → better student results
  • Affordable, fast access to essential medication

1.500.000 €

Total requerido

5000 €

Mínimo por inversor
Más información
Cure For Paralysis

Cure For Paralysis

location_onIsrael

Matricelf develops the first autologous (self) neural implant to repair spinal cord injuries. Backed by strong preclinical data and heading toward First-in-Human trials in early 2026, a key inflection point.

  • The 1st to develop functional neuronal tissue (Micro-Spinal Cord)
  • Autologous (self). Made from the patient own cells. No rejection.
  • 3d structure to accelerate integration.

2.600.000 €

Total requerido

20.000 €

Mínimo por inversor
Más información
MediPoint UK Limited

MediPoint UK Limited

location_onGran Londres, Reino Unido

MediPoint facilitates easy access to licensed Pharmaceutical Products in the UK at competitive prices.

  • 7 Licences already obtained
  • 5 Licences already applied for
  • Major customers secured

2.300.000 €

Total requerido

300.000 €

Mínimo por inversor
Más información
Loading…
Loading the web debug toolbar…
Attempt #